Novo Nordisk parent refiles US application on Catalent deal
After Novo Holdings set the stage for a $16.5 billion buyout of contract manufacturing giant Catalent earlier this year, its parent company is giving antitrust officials more time for their review with one simple trick.
Catalent Publishes Fifth Annual Corporate Responsibility Report
Pharma companies could turn away from Catalent on the back of its $16.5 billion acquisition by Novo Holdings, which would allow for future opportunities for other CDMOs, Siegfried CEO Wolfgang Wienand said during its earnings call with investors this morning.
Catalent reorg leaves 300 without jobs as CDMO awaits buyout
As Catalent gets ready to join the Novo fold, the contract manufacturing juggernaut continues to slide on its diminishing COVID-19 business.
Astrazeneca says Catalent deal shows need for in-house capacity
One of Catalent’s three sites at the center of the Novo-Catalent deal has been hit by at least three form 483s in the past two years. In the three forms, there were two separate mentions of the site as having failed to review product batch discrepancies, while there were also two different concerns on validating manufacturing equipment.
Eli Lilly has expressed reservations about the Novo-Catalent deal and its potential impact on the wider manufacturing industry.
As part of the acquisition of manufacturing giant Catalent, Novo Nordisk will fork over $11 billion for three of the CDMO’s plants. But one of those facilities has now been flagged for control lapses.